flu

Pharmaceutical companies produce drugs and are increasing involved in the clinical trials of these products. This conflict of interest is incompatible with the expectations  of Public Health. Rony Brauman suggests that the industry no longer be responsible for therapeutic trials.

Based on MSF's experience in responding to epidemics, Jean-Hervé Bradol describes the risks of spending precious time and energy on trying to delay the spread of the epidemic rather than on the case management of large numbers of sick people.

The public arena is once again the stage for discourse and undertakings of Titanic proportions. Some endeavour to adjust our planet's thermostat while others devote themselves to wiping out the scourge of disease.

Influenza A H1N1 is turning into a pandemic. What will the number of cases be, what groups will be the most affected, how virulent will the virus be, and how long will it last?